Sepsis alert system aims to speed up critical care response in hospitals

NCT ID NCT07804251

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether an automated alert, triggered when a patient's sepsis risk score rises, can speed up critical care and improve outcomes. When the alert fires, the bedside nurse can activate a critical care team, and if no response occurs, the team is paged automatically. The study compares this alert-and-response pathway to usual care for adult patients on general wards. The main goal is to see if patients have better health status five days after the alert, such as being discharged or not needing organ support.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An automated sepsis alert that triggers a structured critical care team response, including automatic lab orders and paging if the nurse does not respond.
What this could lead to
If it works, this could lead to earlier treatment for hospital-onset sepsis, potentially reducing deaths and ICU stays, and could become a standard tool in hospitals.
What could go wrong
The trial is large but tests a complex intervention in real-world settings, so results may vary. There is also a risk of alert fatigue or unnecessary antibiotic use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,700 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Admitted to a participating study unit at the time of the qualifying event. Participating units are non-cancer medicine wards (hospitalist, resident, and family medicine), general surgery. * Sepsis prediction score computed by the electronic health record crosses the pre-specified study threshold at any point during the admission Exclusion Criteria: * Comfort-focused or hospice goals of care documented at the time of threshold crossing. Do-not-resuscitate or do-not-intubate status alone is not an exclusion; participants with these orders are eligible, and the responding team tailors its response to documented goals of care * Already receiving intensive-care-level treatment while boarding on a ward unit at the time of threshold crossing * Pre-existing order declining rapid response team activation (expected to be exceedingly rare) Participants are identified automatically by the electronic health record at the time of threshold crossing. There is no active recruitment, no study visit, and no contact between participants and the study team. Eligibility is evaluated by rule from electronic health record data, identically in both arms.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clinical Deterioration Critical Illness infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • OHSU Hospital

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.